Header Logo

Connection

JOHN VIERLING to Genotype

Back to Details
This is a "connection" page, showing publications JOHN VIERLING has written about Genotype.
JOHN VIERLING
Connection Strength
0.713
Genotype
  1. Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response. J Hepatol. 2014 Apr; 60(4):748-56.
    View in: PubMed
    Score: 0.068
  2. PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-na?ve HCV genotype 1/4 patients. Hepatology. 2013 Aug; 58(2):524-37.
    View in: PubMed
    Score: 0.066
  3. JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-na?ve HCV genotype 1/4 patients. Hepatology. 2013 Aug; 58(2):514-23.
    View in: PubMed
    Score: 0.066
  4. Hepatitis C virus viral assays in the direct-acting antiviral era. Clin Liver Dis. 2013 Feb; 17(1):27-45.
    View in: PubMed
    Score: 0.064
  5. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin. Hepatology. 2012 Aug; 56(2):464-73.
    View in: PubMed
    Score: 0.061
  6. Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: Integrated analysis from clinical trials. J Viral Hepat. 2020 11; 27(11):1222-1233.
    View in: PubMed
    Score: 0.027
  7. Elbasvir/grazoprevir in black adults with hepatitis C virus infection: a pooled analysis of phase 2/3 clinical trials. Am J Gastroenterol. 2018 06; 113(6):863-871.
    View in: PubMed
    Score: 0.023
  8. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N Engl J Med. 2018 01 25; 378(4):354-369.
    View in: PubMed
    Score: 0.023
  9. The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. J Gastroenterol. 2018 May; 53(5):679-688.
    View in: PubMed
    Score: 0.023
  10. Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials. Lancet Gastroenterol Hepatol. 2017 11; 2(11):814-823.
    View in: PubMed
    Score: 0.022
  11. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N Engl J Med. 2017 06 01; 376(22):2134-2146.
    View in: PubMed
    Score: 0.022
  12. Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection. Ann Hepatol. 2016 Nov-Dec 2016; 15(6):834-845.
    View in: PubMed
    Score: 0.021
  13. Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection. Gastroenterology. 2017 01; 152(1):164-175.e4.
    View in: PubMed
    Score: 0.021
  14. Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial. J Viral Hepat. 2016 Feb; 23(2):80-8.
    View in: PubMed
    Score: 0.019
  15. Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-na?ve patients with chronic HCV genotype 1 infection (ESSENTIAL II). Aliment Pharmacol Ther. 2015 Oct; 42(7):829-44.
    View in: PubMed
    Score: 0.019
  16. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. 2015 May 05; 313(17):1736-44.
    View in: PubMed
    Score: 0.019
  17. Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders. J Hepatol. 2015 Jul; 63(1):30-7.
    View in: PubMed
    Score: 0.019
  18. Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin. J Hepatol. 2015 Feb; 62(2):294-302.
    View in: PubMed
    Score: 0.018
  19. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut. 2015 Jun; 64(6):948-56.
    View in: PubMed
    Score: 0.018
  20. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. J Hepatol. 2014 Dec; 61(6):1238-46.
    View in: PubMed
    Score: 0.018
  21. The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. Gastroenterology. 2014 Aug; 147(2):366-76.e6.
    View in: PubMed
    Score: 0.017
  22. Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-a2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial. Antivir Ther. 2013; 18(3):387-97.
    View in: PubMed
    Score: 0.016
  23. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clin Gastroenterol Hepatol. 2013 Jan; 11(1):81-87.e4; quiz e5.
    View in: PubMed
    Score: 0.016
  24. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011 Mar 31; 364(13):1207-17.
    View in: PubMed
    Score: 0.014
  25. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology. 2010 Sep; 52(3):822-32.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.